An internal standard for the quantification of oxonic acid
Related Products
Unlabeled Version(s)
22586Oxonic Acid (potassium salt)
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Oxonic Acid-13C2,15N3 (potassium salt hydrate)

Item No. 33282

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
1,4,5,6-tetrahydro-4,6-dioxo-1,3,5-triazine-4,6-13C2-1,3,5-15N3-2-carboxylic acid, monopotassium salt, hydrate
Synonyms
  • Allantoxanic Acid-13C2,15N3
  • Potassium oxonate-13C2,15N3
Molecular Formula
C2[13C]2H2[15N]3O4 • K [XH2O]
Formula Weight
200.1
Purity
≥95%
Formulation
A solid
Solubility(Learn about Variance in Solubility)
Water: slightly soluble
SMILES
O=[13C]([15N]=C(C([O-])=O)[15NH]1)[15NH][13C]1=O.[K+].O
InChi Code
InChI=1S/C4H3N3O4.K.H2O/c8-2(9)1-5-3(10)7-4(11)6-1;;/h(H,8,9)(H2,5,6,7,10,11);;1H2/q;+1;/p-1/i3+1,4+1,5+1,6+1,7+1;;
InChi Key
KAISPCXZDYMVOB-YKHLTIOGSA-M
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $334

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Oxonic acid-13C2,15N3 is intended for use as an internal standard for the quantification of oxonic acid (potassium salt) (Item No. 22586) by GC- or LC-MS. Oxonic acid is a uricase inhibitor (IC50 = 0.8 µM) that prevents metabolism and excretion of uric acid.1,2 It also inhibits orotate phosphoribosyltransferase (ORPT), reducing OPRT-mediated phosphorylation of 5-fluorouracil (5-FU; Item No. 14416) in Yoshida sarcoma cell extracts with an IC50 value of 3.7 µM.3 Oxonic acid (10-50 mg/kg) decreases the severity of gastrointestinal tract injury and the incidence of diarrhea induced by the 5-FU prodrug tegafur (Item No. 26076) and uracil (Item No. 26088) without loss of antitumor activity in a rat Yoshida sarcoma model. It has also been used to induce hyperuricemia in rodents.4 Formulations containing oxonic acid have been used in the treatment of head, neck, lung, pancreatic, gastric, and breast carcinomas.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Johnson, W.J., and Chartrand, A. Allantoxanamide: A potent new uricase inhibitor in vivo. Life Sci. 23(22), 2239-2244 (1978).

    2. Gralla, E.J., and Crelin, E.S. Oxonic acid and fetal development: I. Embryotoxicity in mice. Toxicology 6(3), 289-297 (1976).

    3. Shirasaka, T., Shimamoto, Y., and Fukushima, M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 53(17), 4004-4009 (1993).

    4. Stavric, B., and Nera, E.A. Use of the uricase-inhibited rat as an animal model in toxicology. Clin. Toxicol. 13(1), 47-74 (1978).